Tirzepatide (Zepbound® & Mounjaro®) for Weight Loss in Northern Virginia
Tirzepatide — sold as Zepbound® for weight loss and Mounjaro® for type 2 diabetes — is the most effective weight-loss medication available today, with average weight loss of about 21% of body weight in clinical trials. That approaches the territory once reserved for surgery. At Virginia Bariatric Center in Herndon, tirzepatide is prescribed and managed by Dr. Matthew Fitzer, a fellowship-trained, board-certified bariatric surgeon, as part of a comprehensive medical weight-loss program — with in-office and telehealth visits for patients across Northern Virginia and the Washington, D.C. metro area, including Herndon, Reston, Fairfax, Loudoun, Arlington, and Alexandria.
What is tirzepatide and how does it work?
Tirzepatide is the first dual GIP and GLP-1 receptor agonist — it activates two gut-hormone receptors, and therefore two weight-loss pathways, instead of one. Like GLP-1 medications such as semaglutide (Wegovy), it curbs appetite, slows stomach emptying, and quiets “food noise.” The added GIP activity appears to amplify weight loss and improve how the body handles fat and sugar — which is why tirzepatide outperforms single-pathway medications in trials. It’s taken as a once-weekly injection with a pre-filled pen, starting at a low dose and stepping up gradually over several months.
Zepbound vs. Mounjaro: what’s the difference?
- Zepbound® is FDA-approved for chronic weight management — and also for moderate-to-severe obstructive sleep apnea in adults with obesity, the first medication ever approved for OSA.
- Mounjaro® is the same molecule approved for type 2 diabetes.
If you’ve been told “Mounjaro for weight loss,” what you likely need is Zepbound — same active ingredient, but the correct indication matters enormously for insurance approval. Our office handles that paperwork daily.
How much weight will I lose on tirzepatide?
The trial data is the strongest ever recorded for a weight-loss medication:
- In SURMOUNT-1, adults on the highest dose lost an average of about 21% of body weight over 72 weeks; more than half lost 20% or more.
- In SURMOUNT-5, the first head-to-head trial against semaglutide, tirzepatide produced 20.2% average weight loss vs. 13.7% for Wegovy — about 50 pounds vs. 33 pounds for the average participant.
For a 250-pound patient, average results equate to roughly 50 pounds. Individual results vary with dose, genetics, and lifestyle — and while tirzepatide narrows the gap, bariatric surgery still produces larger, more durable weight loss for many patients. Because Dr. Fitzer offers both, you’ll get an honest comparison, not a sales pitch — see his analysis in Wegovy vs. Surgery Outcomes.
Health benefits beyond the scale
- Sleep apnea. Zepbound is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity — in trials it substantially reduced breathing interruptions, and many patients reduce or eliminate CPAP dependence.
- Blood sugar. Tirzepatide produces powerful A1c reductions and can prevent progression from prediabetes to diabetes.
- Metabolic health. Trials show meaningful improvements in blood pressure, triglycerides, cholesterol, and waist circumference.
- Patients routinely report better energy, less joint pain, and improved mobility as weight comes down.
Who is a candidate for tirzepatide?
Zepbound may be right for you if you have a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related condition such as high blood pressure, sleep apnea, or high cholesterol — or if you have moderate-to-severe obstructive sleep apnea with obesity. Selected patients with a BMI under 27 are also candidates. It should not be used during pregnancy or with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, and a history of pancreatitis or significant GI disease needs careful evaluation first. Every prescription at our practice follows a full medical evaluation — check Do I qualify? or request an appointment.
Side effects and safety: why supervision matters
Tirzepatide’s side-effect profile is similar to other GLP-1 medications — mostly mild and related to digestion (nausea, constipation, diarrhea), most noticeable during dose increases, and generally improving with time. In the head-to-head trial its tolerability was comparable to semaglutide’s. Less common risks include gallbladder disease and pancreatitis. Because weight loss on tirzepatide can be rapid, protecting muscle mass with adequate protein and strength activity is a core part of our protocol — our dietitian sets targets and we monitor progress at follow-ups. Dr. Fitzer also tracks emerging safety research on GLP-1s closely and writes about it candidly in Dr. Fitzer Dissects the News.
Tirzepatide vs. semaglutide: which should you choose?
Head-to-head, tirzepatide wins on average weight loss (20.2% vs. 13.7% in SURMOUNT-5). But the right choice is individual:
- Choose tirzepatide when maximum weight loss is the priority, or when sleep apnea is part of the picture.
- Semaglutide may fit better when your insurance covers it preferentially, or when established cardiovascular disease makes Wegovy’s proven heart-protection data (SELECT trial) decisive.
- Coverage often decides. Formularies frequently prefer one over the other; we prescribe both and will match the medication to your coverage and your health profile.
Read more about semaglutide (Wegovy & Ozempic) or see all weight-loss medications we prescribe.
When medication isn’t enough
Tirzepatide is a powerful tool, but it’s not a good fit for everyone. Some patients are unresponsive to it and plateau short of their health goals. Others can’t tolerate the medication because of nausea or other side effects. For many, long-term tirzepatide is just too expensive. This is where our practice is different: as a full-service bariatric center, we will speak frankly about when tirzepatide isn’t likely to help you achieve your goals. There are times when opting for a gastric sleeve or gastric bypass is wiser overall than continuing to escalate medication. Obesity is a chronic disease; the best treatment is the one you can sustain for the long, long term.
Cost and insurance coverage in Virginia
Commercial coverage for Zepbound continues to improve, especially with the sleep-apnea indication — prior authorization is usually required, and our office manages it. As of 2026, a Medicare pilot program covers GLP-1s for weight management for eligible beneficiaries, and manufacturer self-pay options (including single-dose vials at reduced prices) have made out-of-pocket treatment far more affordable than list price. We also prescribe affordable non-GLP-1 alternatives for patients who need a lower-cost option or cannot use a GLP-1. Start with our insurance coverage guide — we’ll help you find the lowest-cost path to treatment.
Tirzepatide FAQs
Is Zepbound stronger than Wegovy?
In the only head-to-head trial (SURMOUNT-5), tirzepatide (Zepbound) produced greater average weight loss than semaglutide (Wegovy): 20.2% vs. 13.7% of body weight at 72 weeks. Individual responses vary, and factors like insurance coverage, tolerability, and cardiovascular history can make either the better choice for a given patient.
How do I get a tirzepatide prescription in Northern Virginia?
Start with a medical evaluation at Virginia Bariatric Center — in person in Herndon or by telehealth anywhere in Virginia. We review your history, labs, and goals; if tirzepatide is appropriate, we prescribe it, handle prior authorization, and follow you closely through dose escalation.
Will I regain weight if I stop Zepbound?
In the SURMOUNT-4 trial, patients who stopped tirzepatide regained a substantial portion of lost weight within a year, while those who continued kept losing. Obesity behaves like a chronic condition — which is why we plan maintenance from your first visit, whether that means ongoing medication, a taper strategy, or discussing more durable surgical options. Dr. Fitzer's weight-regain series covers this honestly.
Does Zepbound really treat sleep apnea?
Yes. Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity — the first medication approved for OSA. In trials it markedly reduced apnea events, and some patients were able to reduce or discontinue CPAP under physician guidance. If you snore, wake unrefreshed, or use CPAP, mention it at your visit — it may also strengthen your insurance approval.
Is compounded tirzepatide safe?
We prescribe only FDA-approved tirzepatide (Zepbound, Mounjaro). With the shortage resolved, mass-compounded versions are no longer permitted, and compounded products were never FDA-reviewed for purity or dosing accuracy. Manufacturer self-pay programs have narrowed the price gap — ask us before considering an unregulated source.
Can tirzepatide help with weight regain after bariatric surgery?
Yes — GLP-1-class medications are increasingly used for post-surgical weight regain, and a bariatric surgeon is uniquely positioned to manage this: we can evaluate whether the regain is anatomic, behavioral, or metabolic, and treat accordingly. Learn more about our revision surgery and medical-management options.
Next steps: start tirzepatide with the region’s weight-loss experts
One visit gets you a clear answer on candidacy, coverage, and what results you can realistically expect. Request an appointment or call (703) 709-9771. Serving Herndon, Reston, Fairfax, Loudoun, Arlington, Alexandria, and the greater Washington, D.C. metro area — telehealth available throughout Virginia.